Analysts Offer Predictions for Q32 Bio FY2029 Earnings

Q32 Bio Inc. (NASDAQ:QTTB) – Analysts at HC Wainwright issued their FY2029 earnings per share (EPS) estimates for Q32 Bio in a research report issued to clients and investors on Wednesday, February 25th. HC Wainwright analyst J. Pantginis forecasts that the company will post earnings per share of ($0.18) for the year. HC Wainwright has a “Buy” rating and a $13.00 price objective on the stock. The consensus estimate for Q32 Bio’s current full-year earnings is ($12.32) per share. HC Wainwright also issued estimates for Q32 Bio’s FY2030 earnings at $0.11 EPS.

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Q32 Bio in a research report on Friday, January 9th. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Q32 Bio presently has an average rating of “Hold” and a consensus target price of $14.00.

Q32 Bio Stock Performance

QTTB stock opened at $4.73 on Thursday. Q32 Bio has a 1 year low of $1.35 and a 1 year high of $6.37. The firm has a market cap of $58.18 million, a P/E ratio of -1.37 and a beta of 0.16. The stock has a 50-day simple moving average of $3.75 and a 200-day simple moving average of $2.86.

Insider Activity

In related news, CFO Lee Kalowski sold 9,072 shares of the stock in a transaction dated Tuesday, December 2nd. The stock was sold at an average price of $3.46, for a total value of $31,389.12. Following the completion of the transaction, the chief financial officer owned 39,938 shares of the company’s stock, valued at approximately $138,185.48. This represents a 18.51% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Jodie Pope Morrison sold 22,506 shares of the firm’s stock in a transaction that occurred on Tuesday, December 2nd. The shares were sold at an average price of $3.46, for a total value of $77,870.76. Following the sale, the chief executive officer owned 99,000 shares of the company’s stock, valued at approximately $342,540. This trade represents a 18.52% decrease in their position. The SEC filing for this sale provides additional information. Insiders own 40.00% of the company’s stock.

Institutional Trading of Q32 Bio

Several institutional investors and hedge funds have recently bought and sold shares of the company. Opaleye Management Inc. acquired a new position in Q32 Bio in the fourth quarter worth $708,000. Monaco Asset Management SAM increased its stake in Q32 Bio by 17.1% during the second quarter. Monaco Asset Management SAM now owns 591,937 shares of the company’s stock valued at $882,000 after purchasing an additional 86,486 shares during the last quarter. Renaissance Technologies LLC raised its holdings in shares of Q32 Bio by 110.6% during the fourth quarter. Renaissance Technologies LLC now owns 99,600 shares of the company’s stock worth $331,000 after purchasing an additional 52,300 shares during the period. Jane Street Group LLC bought a new position in shares of Q32 Bio in the 2nd quarter worth about $69,000. Finally, AQR Capital Management LLC bought a new position in shares of Q32 Bio in the 1st quarter worth about $68,000. Institutional investors and hedge funds own 31.32% of the company’s stock.

About Q32 Bio

Q32 Bio Inc, a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis.